Atara Biotherapeutics (ATRA) shares were down almost 10% Tuesday after its active investigational new drug applications were placed on clinical hold by the US Food and Drug Administration.
The INDs cover Ebvallo, a treatment for patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease, and the ATA3219 drug product for non-Hodgkin's lymphoma and systemic lupus erythematosus, the company said.
The clinical hold for both programs comes amid "compliance issues" at a third-party manufacturing facility, Atara said.
Atara said new patient recruitment for both programs have been suspended while participants in the clinical trials with potential clinical benefit may continue receiving treatment according to established study protocols.
Price: 5.95, Change: -0.63, Percent Change: -9.51
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。